Syndax Pharmaceuticals (NASDAQ: SNDX) has pulled back after a period of gains, with investors now focused on clinical data expected in the fourth quarter. The commercial performance and label expansion of Revuforj and Niktimvo, together with development progress for next-generation menin and EGFR inhibitors, will shape expectations for the company's revenue growth and valuation.
As of September 25, 2026, SNDX was down 14% for the year, after trading as much as 20% above its year-start level at an April peak. From its July 2025 level, however, the stock has still more than doubled. The contrasting moves reflect both expectations for growth from commercial products and renewed scrutiny of near-term uncertainty ahead of clinical readouts.
Revuforj posts high response rate in AML study
Revuforj is one of Syndax's key products, and management has reiterated that peak U.S. sales could exceed $2 billion. Recently released data from the SAVE trial have become one of the main supports for that expectation.
In the acute myeloid leukemia (AML) study, Revuforj produced an 88% overall response rate (ORR) and showed a strong rate of minimal residual disease (MRD) negativity. For AML therapies, response rates and MRD status are important measures of treatment depth. The results have eased some market concerns about partial results from the ongoing Phase 3 trial and provide additional data for assessing the drug's potential use in real-world treatment.
The SAVE results do not, however, establish success across all future indications or registration studies. Revuforj's commercial value will still depend on whether further trials reproduce the observed efficacy, the outcome of regulatory review, and the pace at which physicians and patients adopt the treatment.
Q4 readouts will focus on GVHD and IPF
The next major catalysts include data on Revuforj in graft-versus-host disease (GVHD) and idiopathic pulmonary fibrosis (IPF). Because these readouts could materially affect the valuation of the pipeline, they also create event-specific risk. Results showing weaker efficacy or safety than expected could lead the market to lower its revenue assumptions for the indications, while data in line with expectations would support Syndax's strategy of expanding Revuforj into additional diseases.
Syndax's other marketed product, Niktimvo, is also part of the company's revenue base. As sales from the approved products accumulate, investors will assess whether the two products can build a broader revenue stream and reduce the company's reliance on a single clinical program or indication.
New inhibitors broaden development options
Beyond its existing products, Syndax is advancing next-generation menin inhibitor and EGFR inhibitor programs. The projects target disease areas including myelofibrosis and non-small cell lung cancer (NSCLC), where significant unmet treatment needs remain.
These programs could reach proof-of-concept milestones on relatively shorter development timelines. If early data arrive quickly, they could provide another basis for valuation. At the early- or mid-stage of development, however, the programs remain exposed to questions about efficacy, safety, trial design and changes in the competitive landscape. Their pipeline potential cannot yet be treated as committed revenue.
Competition and clinical data remain key variables
The bull case for SNDX rests mainly on rising contributions from Revuforj and Niktimvo, broader indications for Revuforj and additional growth options from the company's later-stage pipeline. Syndax also faces competition in NPM1-related markets, while the GVHD and IPF readouts could produce notable share-price swings.
The market's view of Syndax therefore depends on more than a single AML dataset. Investors will also be watching the fourth-quarter clinical readouts, progress in Phase 3 trials, actual product sales and the company's ability to convert multiple programs into recurring revenue. Although SNDX has more than doubled from its July 2025 level, it remains 14% below its 2026 high; ahead of the next data releases, the shares are likely to remain sensitive to both clinical results and commercial execution.